Vaxess Technologies
Mark is Director for the Center for Vaccine Equity at the Task Force for Global Health in Decatur, GA. Mark also serves as Director of The Task Force’s Polio Eradication program. Prior to joining the Task Force, Mark was co-founder, Chief Scientific Officer and Senior Vice President for Research and Development of TetraLogic Pharmaceuticals, co-founder and Vice President of R&D of ViroPharma Incorporated (acquired in 2014 by Shire) and Senior Director, Virology and Oncopharmacology in the research group at Sterling Drug where he discovered a novel class of antipicornavirus agents presently being developed to treat poliovirus infections in immune deficient poliovirus excreters.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Vaxess Technologies
Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. They are committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world.